Thailand’s Food and Drug Administration (FDA) has published a consolidated list of substances that successfully passed novel food safety evaluation. The list is a step forward in regulatory transparency. Unfortunately, each approval is tied exclusively to the company that applied for it. As such, a novel food substance on the list does not give other companies the green light to use it.
Notification No. 376 of the Ministry of Public Health requires novel foods to undergo a food safety assessment, with an exemption only for those manufactured exclusively for export. The framework also encompasses ‘foods that do not qualify as novel foods’ but which present characteristics warranting a safety evaluation, such as differing quality standards, increased serving sizes, or applications in specific food categories, where such changes affect consumption levels, nutritional value, or consumer safety.
The recently published list of foods that passed the safety evaluation by the Thai FDA is structured by substance category and identifies the approved company (domestic manufacturer or importer), country of origin, substance name and trade name, approved purpose of use, and date of the Thai FDA’s approval notification certificate.
A striking feature of Thailand’s novel food regime is that the approval result is tied exclusively to the company that submitted the application. Publication of the consolidated list does not constitute a general authorization to use the approved substances. The Thai FDA’s approval certificate specifies the approved conditions of use and the requirements to support food product registration, and it remains tied to the applicant’s company alone. Other companies cannot rely on the public list as a basis for using the same substance without consent (an authorization letter) from the original approval holder.
This exclusivity creates a regulatory challenge for 3rd party food companies that wish to incorporate the same food substance, even though it has already been evaluated and approved for another entity.
The Thai FDA however recognizes 2 pathways to use a previously approved novel food substance. The first pathway is to get consent from the original applicant. The 3rd party must present a copy of the applicant’s approval notification certificate to support its own product registration application, together with the consent letter. This pathway effectively requires a commercial relationship via a supply or licensing agreement with the original applicant. The second pathway is via independent safety assessment which is more time consuming and costly, as it needs to submit its own safety assessment for the same substance. It may do so by filing a request with a certified safety evaluation unit recognized by the Thai FDA, and submitting the evaluation report, along with supporting documentary evidence, for the Thai FDA’s consideration.
The absence of any referencing mechanism raises the barrier to entry for later participants and, in effect, treats safety evaluation outcomes as proprietary to the applicant—giving first mover advantage in the novel food ingredient market.
As such, companies that plan to use novel food substances in their product formulations should first check whether the desired substance has already been approved. If it has, they should establish early and robust commercial relationships with the approved manufacturer or importer. Otherwise, it needs to pursue its own independent safety assessment.